AU2021374232A1 - Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof - Google Patents

Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof Download PDF

Info

Publication number
AU2021374232A1
AU2021374232A1 AU2021374232A AU2021374232A AU2021374232A1 AU 2021374232 A1 AU2021374232 A1 AU 2021374232A1 AU 2021374232 A AU2021374232 A AU 2021374232A AU 2021374232 A AU2021374232 A AU 2021374232A AU 2021374232 A1 AU2021374232 A1 AU 2021374232A1
Authority
AU
Australia
Prior art keywords
formula
compound
group
reaction
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021374232A
Other languages
English (en)
Other versions
AU2021374232A9 (en
Inventor
Christian GRUGEL
Tobias Wedel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actinogen Medical Ltd
Original Assignee
Actinogen Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020904060A external-priority patent/AU2020904060A0/en
Application filed by Actinogen Medical Ltd filed Critical Actinogen Medical Ltd
Publication of AU2021374232A1 publication Critical patent/AU2021374232A1/en
Publication of AU2021374232A9 publication Critical patent/AU2021374232A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B49/00—Grignard reactions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2021374232A 2020-11-06 2021-11-05 Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof Pending AU2021374232A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020904060A AU2020904060A0 (en) 2020-11-06 Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof
AU2020904060 2020-11-06
PCT/AU2021/051310 WO2022094668A1 (en) 2020-11-06 2021-11-05 Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof

Publications (2)

Publication Number Publication Date
AU2021374232A1 true AU2021374232A1 (en) 2023-06-08
AU2021374232A9 AU2021374232A9 (en) 2024-09-26

Family

ID=81458249

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021374232A Pending AU2021374232A1 (en) 2020-11-06 2021-11-05 Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof

Country Status (11)

Country Link
US (1) US20230416243A1 (https=)
EP (1) EP4240740A4 (https=)
JP (1) JP2023548368A (https=)
KR (1) KR20230154789A (https=)
CN (1) CN116981461A (https=)
AU (1) AU2021374232A1 (https=)
CA (1) CA3196642A1 (https=)
CL (1) CL2023001300A1 (https=)
IL (1) IL302671A (https=)
MX (1) MX2023004940A (https=)
WO (1) WO2022094668A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025073002A1 (en) * 2023-10-03 2025-04-10 Actinogen Medical Limited Tablet formulation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026509196A (ja) * 2023-03-02 2026-03-17 アクチノゲン メディカル リミテッド アザ二環式ヘテロアリール化合物を調製するための流動化学プロセス

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7410961B2 (en) * 2004-01-20 2008-08-12 Merck & Co., Inc. 2,6-disubstituted piperiddines as modulators
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
ES2366058T3 (es) * 2006-03-01 2011-10-14 Theravance, Inc. Compuestos de 8-azabiciclo[3.2.1]octano como antagonistas de los receptores opioides mu.
AR073920A1 (es) * 2008-10-23 2010-12-09 Boehringer Ingelheim Int Derivados urea de nortropanos sustituidos, medicamentos que contienen dichos compuestos , su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa y proceso para su preparacion.
US8642621B2 (en) * 2009-09-16 2014-02-04 The University Of Edinburgh (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use
KR101445012B1 (ko) * 2009-12-17 2014-09-26 머크 샤프 앤드 돔 코포레이션 Ｓｙｋ 억제제로서의 아미노피리미딘
EP2525659B1 (en) * 2010-01-19 2019-02-27 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
AU2011247116B2 (en) * 2010-04-29 2015-12-03 The University Of Edinburgh 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1H - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -HSD1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025073002A1 (en) * 2023-10-03 2025-04-10 Actinogen Medical Limited Tablet formulation

Also Published As

Publication number Publication date
US20230416243A1 (en) 2023-12-28
WO2022094668A1 (en) 2022-05-12
IL302671A (en) 2023-07-01
MX2023004940A (es) 2023-09-12
CN116981461A (zh) 2023-10-31
CL2023001300A1 (es) 2024-01-05
EP4240740A4 (en) 2024-12-11
JP2023548368A (ja) 2023-11-16
KR20230154789A (ko) 2023-11-09
CA3196642A1 (en) 2022-05-12
EP4240740A1 (en) 2023-09-13
AU2021374232A9 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
EP4279488A1 (en) Synthesis method for aminopyrimidine fak inhibitor compound
TW201713652A (zh) 雜環化合物的合成
US20190135806A1 (en) Solid state forms of venetoclax and processes for preparation of venetoclax
CN102311448B (zh) 噻吩并嘧啶酮类dpp-iv抑制剂
CN106946917A (zh) 一种jak抑制剂巴瑞替尼及其中间体的新合成方法
ES2769255T3 (es) Métodos para fabricar inhibidores de la proteína desacetilasa
EP3766869A1 (en) Simple preparation method for avibactam
AU2021374232A9 (en) Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof
CN102725288A (zh) 用于制造6-取代的1-甲基-1h-苯并咪唑衍生物的方法和所述方法的中间体
CN106795174B (zh) 一种抗病毒活性双氮氧杂环螺二酮哌嗪生物碱衍生物及其制备方法
AU2023351959A1 (en) Synthesis methods and intermediates for the production of remibrutinib
CN104876872B (zh) 一种制备1‑叔丁氧基羰基‑3‑羟甲基吲唑的方法及应用
US20260001882A1 (en) Process for preparing bicyclic glycine-proline compounds and monocyclic glycine-proline intermediates thereof
US20210147466A1 (en) Improved processes for the preparation of guadecitabine and intermediates thereof
KR20210058817A (ko) 브로모도메인 억제제의 제조 방법
US20250304538A1 (en) Process of preparing remibrutinib substantially free of nitrosamine impurity
CA3268617A1 (en) Synthesis methods and intermediates
WO2026082013A1 (zh) 一种酞嗪酮类prmt5抑制剂及其中间体的制备方法
CN119859139A (zh) 双盐酸安罗替尼的固体形式及其制备方法
CN121511241A (zh) 化合物的新制备方法及新结晶形式
CN116568298A (zh) 用于制备4-(3,5-二氟苯基)-N-[3-(6-甲基嘧啶-4-基)-3-氮杂双环[3.2.1]辛烷-8-基]-6,7-二氢-5H-[1,2,4]三唑并[1,5-a]嘧啶-2-胺的方法
CN117736221A (zh) 瑞卢戈利中间体化合物及瑞卢戈利的制备方法
CN121991162A (zh) 一种药物偶联物中间体及制备方法
WO2013140331A1 (en) New 1, 2, 4-oxadiazol derivatives, process for their preparation and use thereof as intermediates in the preparation of indolic alkaloids
CN119638647A (zh) 制备氧杂环丁烷-2-基甲胺或其盐的方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ GRUGEL, CHRISTIAN AND WEDEL, TOBIAS

SREP Specification republished